Synthesis of a Zn(II)-Responsive ParaCEST MRI Agent for Improved Diagnosis of Prostate Cancer by Martin, Megan & Clancy, Holly
Introduction
Holly Clancy, Megan Martin, and Dr. Osasere Evbuomwan
Department of Chemistry, University of San Francisco, 2130 Fulton St., San Francisco, CA 94117
• This work is funded by the Faculty Development Fund at the
University of San Francisco.
• Special thanks to Dr. Evbuomwan for her direction and to the
Department of Chemistry at USF.
1. American Cancer Society. Cancer Facts & Figures 2019: Atlanta: American Cancer Society; 2019.
2. Qaseem, A.; Barry, M. J.; Denberg, T. D.; Owens, D. K.; Shekelle, P.; Clinical Guidelines Committee of the
American College of Physicians Screening for prostate cancer: a guidance statement from the
Clinical Guidelines Committee of the American College of Physicians. Ann. Intern. Med. 2013, 158,
761-769.
3. Merbach, A.S.; Helm, L.; Tóth, É. The Chemistry of Contrast Agents in Medical Magnetic Resonance
Imaging, 2nd ed.; Wiley: West Sussex, United Kingdom, 2013.
4. Costello, L. C.; Franklin, R. B. Zinc is decreased in prostate cancer: an established relationship of prostate
cancer. Expert Opin. Ther. Targets 2011, 21, 51-66.
5. Srivastava, K.; Ferrauto, G.; Harris, S. M.; Longo, D. L.; Botta, M.; Aime, S.; Pierre, V. C. Complete on/off
responsive ParaCEST MRI contrast agents for copper and zinc. Dalton Trans. 2018, 47, 11346-
11357.
• A healthy prostate has a significantly higher
concentration of Zn(II) than other soft tissues in
the body.
• Zinc (II) levels have been found to be significantly
decreased in the presence of prostate cancer.
• The goal of this project is to synthesize a
ParaCEST MRI agent capable of detecting and
quantifying zinc in the prostate.
• We hypothesize that binding zinc will alter CEST
spectrum, and this will be correlated with the
extent of prostate disease. 4
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Methods
• Prostate cancer accounts for 20 percent of diagnosed cancer cases, the highest rate of diagnosis for all cancers that affect
men.1
• The Prostate Specific Antigen (PSA) test is used for diagnosis of prostate cancer. If the concentration of PSA in the blood is
above a given threshold, the health of the prostate is analyzed with a biopsy.
• 80 percent of positive PSA tests are false positives. The biopsy process is invasive and can cause complications like bleeding
and anxiety.2
• There is an urgent need for a more accurate diagnostic test for prostate cancer.
Results and Discussion
Synthesis of a Zn(II)-Responsive ParaCEST MRI Agent for Improved Diagnosis of 
Prostate Cancer
• CEST Agents represent a new class of MRI contrast agents
that induce negative contrast in an image.
• CEST signal is generated through slow exchange of the
bound protons on an agent with the bulk water protons in
the body.
• Major advantages of CEST agents over clinical MRI
contrast agents include:
• Their ability to be turned “on” and “off” by the
application of a radiofrequency pulse.
• Their sensitivity to the chemical environment in which
they are located.
• ParaCEST agents are CEST agents consisting of a
lanthanide ion chelated by a multidentate ligand. Use of
paramagnetic lanthanides shifts the CEST signal away
from the bulk water signal.5
• An MRI is obtained using a magnet to align the protons of the bulk water in the body, then sending a radio wave frequency
pulse through the body to spin these protons.
• The time required for the protons to return to their original alignment is the relaxation time (T1), and its inverse is the relaxivity
(R1∝ 1/T1), which corresponds to the amount of contrast in an image. 3
• Repeat synthesis for higher yield
• Complexation with lanthanide metal ions
• Titration with ZnCl2, Mg2+, Ca2+, and Cu2+ to confirm selective
binding to Zn2+
• Analyze CEST spectra of agent in absence and presence of Zn2+
(nmols/g wet tissue) Zinc
Normal peripheral zone 3,000-4,500
Malignant peripheral zone 400-800
Normal prostatic fluid 8,000-10,000
Prostate cancer prostatic fluid 800-2,000
Other tissues 200-400
Blood plasma 15
• All reagents were purchased from
commercial suppliers.
• The proposed compounds will be
synthesized according to the scheme in
Figure 4.
• 13C-NMR and 1H-NMR spectroscopy
was used to characterize the
intermediate products.
• Flash chromatography was used to
purify MMHC-2 and MMHC-5
Figure 1: A) random alignment of protons B) application of magnetic field and alignment of protons with field C) application of
radio frequency pulse and spinning of protons D) relaxation of protons to alignment with magnetic field
ReferencesFuture Work
Figure 2: Relationship between prostate health and zinc concentrations
(nmol/g wet tissue). Table indicates tremendous decrease in zinc
concentration with diminishing prostate health.4
Figure 3: CEST spectrum, observed increase in CEST signal, or
bound water signal (left) with decrease in bulk water signal
(right). Observed shift of bound water signal away from bulk
water signal. 5
• Compounds MMHC-1 through
MMHC-5 have been synthesized
successfully and characterized
by 13C-NMR and 1H-NMR
spectroscopy.
• 13C-NMR and 1H-NMR spectra
of compounds MMHC-1 through
MMHC-3 are not shown, but
were used to verify compound
identities.
• The >100 % yield of MMHC-1
was attributed to residual
solvent in the final product.
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Figure 5: 1H NMR spectrum of MMHC-4 in CDCl3 at 500 MHz
Figure 7: 1H NMR spectrum of MMHC-5 in CDCl3 at 500 MHz
Figure 6: 13C NMR spectrum of MMHC-4 in CDCl3 at 125 MHz
Figure 8: 13C NMR spectrum of MMHC-5 in CDCl3 at 125 MHz
Figure 4: Complete synthetic scheme for desired coordinated complex. The first step shows over 100% yield, attributed to residual solvent.
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• The 1H-NMR spectrum of
MMHC-5 lacks the expected
amide proton peak. It is
hypothesized that amide protons
are exchanging with another
species present in the sample.
• The absence of the quaternary
and carbonyl carbons in the 13C-
NMR spectrum of MMHC-5 is
possibly due to the longer T1 of
these carbons.
• An additional 13C NMR of
MMHC-5 will be obtained with
the intention of reducing
baseline noise.
